Net profit of Astrazeneca Pharma India declined 26.62% to Rs 38.43 crore in the quarter ended September 2024 as against Rs 52.37 crore during the previous quarter ended September 2023. Sales rose 31.16% to Rs 408.00 crore in the quarter ended September 2024 as against Rs 311.07 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales408.00311.07 31 OPM %12.8816.96 - PBDT60.3560.63 0 PBT51.0356.95 -10 NP38.4352.37 -27 Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live News

Net loss of Astrazeneca Pharma India reported to Rs 11.79 crore in the quarter ended June 2024 as against net profit of Rs 53.86 crore during the previous quarter ended June 2023. Sales rose 31.15% to Rs 387.52 crore in the quarter ended June 2024 as against Rs 295.47 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales387.52295.47 31 OPM %9.8222.76 - PBDT46.3175.19 -38 PBT42.4071.40 -41 NP-11.7953.86 PL Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live News

Astrazeneca Pharma India announced that the Annual General Meeting (AGM) of the company will be held on 8 August 2024.Powered by Capital Market - Live News